Abstract
Cancer can present without symptoms when it is discovered incidentally or as a result of screening. A feature of a symptom of cancer is persistence. Symptoms can be systemic, such as weight loss or fatigue, or organ specific, such as pain or cough. When treatment commences the symptoms of cancer must be distinguished from the side effects of therapy. These can be characterised by their temporal relation to the treatment as immediate, delayed by days, weeks of months or late effects which occur years later. These symptoms and side effects in turn must be distinguished from the symptoms of concomitant illnesses or side effects of other medication. A multidisciplinary approach is commonly used to manage cancer and parallel care between palliative care clinicians and oncologist is an ideal model for symptom control. Maximising quality of life is the overall aim of treating patients with cancer and this includes recognising all of the parameters, such as spiritual well-being, which impact on overall quality of life, and takes into account the balance between the efficacy and toxicity of treatments. Finally, survivorship embraces late physical effects of the cancer and its treatment as well as psychosocial issues and the adjustment to life after a diagnosis of cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ramos M, Arranz M, Taltavull M, March S, Cabeza E, Esteva M. Factors triggering medical consultation for symptoms of colorectal cancer and perceptions surrounding diagnosis. Eur J Cancer Care (Engl). 2010;19:192–199.
Dexter AJ, Cheong J. Neurosurgical involvement with cancer patients. In Robotin M, Olver I, Girgis A, eds. When Cancer Crosses Disciplines. London: Imperial College Press 2009:343–365.
Pipkin CA, Lio PA. Cutaneous manifestations of internal malignancies: An overview. Dermatol Clin. 2008;26:1–15.
Fattal C, Gault D, Leblond C et al. Metastatic paraplegia: care Âmanagement characteristics within a rehabilitation centre. Spinal Cord. 2009;47:115–121.
Park YH, Lee S, Cho EY et al. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status. Cancer Chemother Pharmacol. 2010;66:507–516.
Beckles MA, Spiro SG, Colice GL, Rudd RM. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests and paraneoplastic syndromes. Chest. 2003;123:97S–104S.
Giess CS, Schwartz LH, Bach AM, Gollub MJ, Panicek DM. Patterns of neoplastic spread in colorectal cancer: implications for surveillance CT studies. Am J Roentgenol. 1998;170:987–991.
Long MA, Husband JE. Features of unusual metastases form Âprostate cancer. Br J Radiol. 1999;72:933–941.
Goolsby TV, Lombardo FA. Extravasation of chemotherapeutic agents: prevention and treatment. Semin Oncol. 2006;33:139–143.
Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemoÂtherapy agents. Ann Allergy Asthma Immunol. 2009;102:187–179.
Olver IN. Prevention of chemotherapy-induced nausea and Âvomiting: Focus on fosaprepitant. Ther Clin Risk Manag. 2008;4(2):1–6.
Heuser M, Ganser A, Bokemeyer C. Neutropenia: Review of Âcurrent guidelines. Semin Oncol. 2007;44:148–156.
Keefe DM, Schubert MM, Elting LS, Sonis ST et al; Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109:820–831.
Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced Âalopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology. 2008;17:317–328.
Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumours. Chest. 2008;133:528–538.
Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Periph Nerv Syst. 2008;13:27–46.
Darmon M, Ciroldi M, Thiery G, Schlemmer B, Azoulay E. Clinical review: Specific aspects of acute renal failure in cancer patients. Crit Care. 2006;10:211 (doi:1186/cc4907).
King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist. 2001;6:162–167.
Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: Review of potential cardiac problems. Clin Cancer Res. 2008;14:14–24.
Hildebrand J. Neurologic complications of cancer chemotherapy. Curr Opin Oncol. 2006;18:321–324.
Meirow D, Schiff E. Appraisal of chemotherapy effects on reproductive outcome according to animal studies and clinical data. J Natl Cancer Inst Monogr. 2005;34:21–25.
Travis B, Rabkin CS, Brown LM et al. Cancer survivorship-genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst. 2006;98:15–25.
Fiorino C, Rancati T, Valdaqni R. Predictive models of toxicity in external radiotherapy: dosimetric issues. Cancer. 2009;115:3135–3140.
Kempster PA, Rollison RD. The Lhermitte phenomenon: variant forms and their significance. J Clin Neurosci. 2008;15:379–381.
Enami B, Lyman J, Brown A et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–122.
Friedlander PA, Bansal R, Schwartz L, Wagman R, Posner P, Kemeny N. Gemcitabine-related radiation recall preferentially involves internal tissue and organs. Cancer. 2004;100:1793–1799.
Kaasa S, Brenne E, Lund JA et al. Prospective randomised multicentre trial on a single fraction radiotherapy (8Gy x 1) versus multiple fractions (3Gy x 10) in the treatment of painful bone metastases. Radiother Oncol. 2006;79:278–284.
Brusamolino E, Baio A, Orlandi E et al. Long-term events in adult patients with clinical stage 1A-11A nonbulky Hodgkin’s Âlymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single institution experience. Clin Cancer Res. 2006;12:6487–6493.
Brufsky A. Trastuzumab-based therapy for patients with ÂHER2-positive breast cancer: form early scientific development to foundation care. Am J Clin Oncol. 2010;33:186–195.
Bailey LJ, Sanson-Fisher R, Aranda S, D’Este C, Sharkey K, Schofield P. Quality of life research: types of publication output over time for cancer patients, a systematic review. Eur J Cancer. 2009;Oct 14 [Epub ahead of print].
Cimprich B, Janz NK, Northouse L, Wren PA, Given B, Given CW. Taking CHAGE: A self-management program for women following breast cancer treatment. Psychooncology. 2005;14:704–717.
Whitford HS, Olver IN, Peterson MJ. Spirituality as a core domain in the assessment of quality of life in oncology. Psychooncology. 2008;17:1121–1128.
Little M, Sayers EJ, Paul K, Jordens CFC. On surviving cancer. J R Soc Med. 2000;93:501–503.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Society for Imaging Informatics in Medicine
About this chapter
Cite this chapter
Olver, I.N. (2010). Cancer Symptoms and Side Effects of Treatment. In: Olver, I. (eds) The MASCC Textbook of Cancer Supportive Care and Survivorship. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-1225-1_1
Download citation
DOI: https://doi.org/10.1007/978-1-4419-1225-1_1
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-1224-4
Online ISBN: 978-1-4419-1225-1
eBook Packages: MedicineMedicine (R0)